To assess whether the pharmacology of RMC-7977 permits effective targeting of RAS-GTP in the context of a native tumour microenvironment, we utilized KrasLSL.G12D/+;Trp53flox/flox;Pdx1-cretg/+ (KPF/FC) mice28, a genetically engineered model that rapidly develops autochthonous KrasG12D mutant PDAC. Here, PDX1 is linked to neoplasm.